Potential Beneficial Effects of Resveratrol on Obesity, Metabolic Syndrome and Inflammation - Emphasis on Description of the Molecular Biology Underpinning the Interplay Between Calorie Restriction, SIRT1, STAT5 and the GH/IGF-I Axis
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Resveratrol (Primary)
- Indications Glucose intolerance; Obesity
- Focus Biomarker; Pharmacodynamics
- 30 Mar 2013 New trial record
- 22 Mar 2012 Biomarkers information updated
- 01 Nov 2011 Primary endpoint 'Glucose-infusion-rate' has not been met.